<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27438203</article-id>
      <article-id pub-id-type="pmc">4938280</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20164111</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Dermatopathology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Type 2 leprosy reaction with Sweet's syndrome-like presentation<xref ref-type="fn" rid="fn1">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chiaratti</surname>
            <given-names>Francielle Chiavelli</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Daxbacher</surname>
            <given-names>Egon Luiz Rodrigues</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Neumann</surname>
            <given-names>Antonielle Borges Faria</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jeunon</surname>
            <given-names>Thiago</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Hospital Federal de Bonsucesso (HFB) - Rio de Janeiro
(RJ), Brazil. </aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Mailing address: Egon Luiz Rodrigues Daxbacher, Rua Sete de
Setembro, 98, sala 1.103, Centro, 20050-002 - Rio de Janeiro - RJ, Brazil.
Email: <email>egondax@gmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interests: None</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2016</year>
      </pub-date>
      <volume>91</volume>
      <issue>3</issue>
      <fpage>345</fpage>
      <lpage>349</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2016 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Leprosy is a chronic disease characterized by manifestations in the peripheral
nerves and skin. The course of the disease may be interrupted by acute phenomena
called reactions. This article reports a peculiar case of type 2 leprosy
reaction with Sweet's syndrome-like features as the first clinical manifestation
of leprosy, resulting in a delay in the diagnosis due to unusual clinical
presentation. The patient had clinical and histopathological features
reminiscent of Sweet's syndrome associated with clusters of vacuolated
histiocytes containing acid-fast bacilli isolated or forming globi. Herein, it
is discussed how to recognize type 2 leprosy reaction with Sweet's syndrome
features, the differential diagnosis with type 1 leprosy reaction and the
treatment options. When this kind of reaction is the first clinical presentation
of leprosy, the correct diagnosis might be not suspected clinically, and
established only with histopathologic evaluation.</p>
      </abstract>
      <kwd-group>
        <kwd>Leprosy</kwd>
        <kwd>Leprosy, multibacillary</kwd>
        <kwd>Sweet syndrome</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Leprosy is a chronic, infectious disease caused by <italic>Mycobacterium
leprae</italic> - acid fast bacilli (AFB) - and characterized by neural and
cutaneous manifestations. The chronic course of the disease can be stopped by acute
phenomena called reactions. Type 1 reactions occur in borderline patients and are
due to variations in cellular immunity; type 2 reactions are mediated by immune
complexes, occur in multibacillary patients and are characterized by diverse
clinical manifestations, being stereotypical the erythema nodosum leprosum (ENL).
Reactions usually appear during or after the treatment of leprosy, but they can also
represent the first manifestation of the disease, making diagnosis more
difficult.<sup><xref rid="r1" ref-type="bibr">1</xref></sup></p>
      <p>Sweet's syndrome, on the other hand, is an acute neutrophilic dermatosis
characterized by painful erythematous edematous plaques, accompanied by fever,
leukocytosis with neutrophilia and infiltrate rich in neutrophils in the dermis,
associated with subepidermal edema of variable intensity. It may be idiopathic or
associated with infections, inflammatory and autoimmune diseases, drugs, neoplasia
and pregnancy.<sup><xref rid="r2" ref-type="bibr">2</xref></sup></p>
      <p>We report a peculiar case of type 2 leprosy reaction with Sweet's syndrome-like
features as the first clinical manifestation of leprosy.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Female patient, 38 years old, residing in Rio de Janeiro, with a history of asthma,
reported that, one year before the medical consultation, intermittent erythematous
lesions on the lower members had appeared, which improved with the use of oral
corticosteroids for asthma attacks. In the previous month, skin lesions became
diffuse and associated with fever, myalgia, nausea and vomiting, without
neurological symptoms. On examination, papules and erythematous edematous plaques
were observed, some with a pseudo-vesicular aspect and others with central pallor,
disseminated over the body, sparing mucosa, palms and soles (<xref ref-type="fig" rid="f1">Figures 1</xref>, <xref ref-type="fig" rid="f2">2</xref> and <xref ref-type="fig" rid="f3">3</xref>). Neurological examination presented no
changes. Blood count showed 11,000 leukocytes with 90% neutrophils, and biochemical
laboratory tests showed no changes. Histopathological examination of the skin
revealed marked edema of the papillary dermis with infiltration of intact and
fragmented neutrophils, in association with groups of vacuolized histiocytes in the
reticular dermis, arranged along the neurovascular bundles. Fite's staining was
positive (5+) for AFB (<xref ref-type="fig" rid="f4">Figures 4</xref>, <xref ref-type="fig" rid="f5">5</xref>, <xref ref-type="fig" rid="f6">6</xref> and
<xref ref-type="fig" rid="f7">7</xref>). We concluded that this is a case of
type 2 leprosy reaction with clinical and histopathological features reminiscent of
Sweet's syndrome.</p>
      <p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Patient with nodules, papules and erythematous edem atous plaques, some
with pseudo vesicles aspect and others with central pallor, affecting
arms and chest</p></caption><graphic xlink:href="abd-91-03-0345-g01"/></fig>
</p>
      <p>
<fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Papules and erythematous edematous plaques affecting the forehead</p></caption><graphic xlink:href="abd-91-03-0345-g02"/></fig>
</p>
      <p>
<fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Erythematous plaques with pale center and pseudo vesicle aspect on the
right arm</p></caption><graphic xlink:href="abd-91-03-0345-g03"/></fig>
</p>
      <p>
<fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Histopathology showing marked edema of the papillary dermis with
superficial and deep inflammatory infiltrate rich in neutrophils
(hematoxylin and eosin, 100x)</p></caption><graphic xlink:href="abd-91-03-0345-g04"/></fig>
</p>
      <p>
<fig id="f5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Infiltration of intact and fragmented neutrophils in the papillary
dermis, and red blood cell extravasation (hematoxylin and eosin,
400x)</p></caption><graphic xlink:href="abd-91-03-0345-g05"/></fig>
</p>
      <p>
<fig id="f6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Deep nodular infiltrate, rich in vacuolated histiocytes (he matoxylin and
eosin, 400x)</p></caption><graphic xlink:href="abd-91-03-0345-g06"/></fig>
</p>
      <p>
<fig id="f7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Numerous acid-fast bacilli(AFB), isolated or forming globi (Fite-Faraco,
400x)</p></caption><graphic xlink:href="abd-91-03-0345-g07"/></fig>
</p>
      <p>The notification of the case was performed and the degree of disability and neural
function was assessed, showing no changes (grade 0). Evaluation of household
contacts (two children) did not present any signs or symptoms of leprosy, and they
were referred to take the second dose of the "bacillus Calmette-Guerin" (BCG)
vaccine. The patient treatment started with multibacillary multidrug therapy and
oral prednisone at a dose of 1 mg/kg/day. Later, pentoxifylline at a dose of 400
mg/day was associated, with gradual increase up to a dose of 400 mg every 8 hours,
in order to slowly reduce the corticosteroid until its complete withdrawal. The
patient presented significant clinical improvement at the end of 2 months of
treatment, but the lesions worsened during the weaning of oral prednisone. It was
proposed starting thalidomide after insertion of intrauterine device and use of
injectable contraceptives. Patient is maintained in outpatient follow-up.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Sweet's syndrome is an acute febrile neutrophilic dermatosis, first described in 1964
by Robert Douglas Sweet.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> Its
characteristics are fever, neutrophilia and painful purplish erythematous plaques.
These plaques may contain pseudo vesicles due to severe edema of the papillary
dermis. With the evolution of the lesions, there may be a central clearing,
resulting in target aspect similar to erythema multiforme.<sup><xref rid="r2" ref-type="bibr">2</xref></sup> The most commonly affected sites are face, neck,
chest, back and upper extremities. Histopathology is characterized by dense
infiltrate of intact and fragmented neutrophils in the superficial and middle dermis
and marked edema in the papillary skin layer. According to the etiology, the
syndrome can be divided into 3 groups: classical (or idiopathic), associated with
malignant disease and drug-induced. The classic form predominates in females and may
be associated with inflammatory and autoimmune diseases, infections - the most
common occurring in the gastrointestinal and upper respiratory tracts - and
pregnancy. Most cases associated with cancer is due to acute myeloid
leukemia.<sup><xref rid="r4" ref-type="bibr">4</xref></sup></p>
      <p>Leprosy reactions are acute immune inflammatory events affecting mainly skin and
nerves. They are the main cause of nerve damage and disability caused by leprosy.
They are classified into 2 major types: type 1 and type 2. Type 1 reaction, or
reversal reaction, occurs in borderline patients as a result of variations in
cellular immunity. It is characterized by reactivation of preexisting lesions or by
the appearance of new lesions, which are erythematous and infiltrated plaques with
swollen appearance. It's possible to occur swelling of the extremities and neuritis,
but , rarely, systemic manifestation.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup> Type 2 reaction is
mediated by immune complexes, occurring in multibacillary patients and presenting
typically as ENL. This is characterized by inflammatory nodules, erythematous and
painful, which can progress to necrosis. Often they are located on face and
extremities and tend to bilateralism and symmetry. Type 2 reaction is often
associated with general symptoms and can show systemic involvement, in particular in
liver and kidney.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup></p>
      <p>There are atypical forms of type 2 reaction, called erythema multiforme-like and
Sweet's syndrome-like reactions. Erythema multiforme-like is characterized by macule
and purplish erithemous plaques, with formation of vesicles and blisters progressing
to necrosis. Target lesions are typical.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref></sup> In non-typical
cases, the condition may be confused with Sweet's syndrome-like reaction.</p>
      <p>Sweet's syndrome-like leprosy reaction was first described in 1987 by Kuo and
Chan.<sup><xref rid="r8" ref-type="bibr">8</xref></sup> The authors reported
a case clinically suggestive of Sweet's syndrome, but with histopathological
features of lepromatous leprosy, associated with edema of the papillary dermis and
dense dermal neutrophilic infiltrate. Since then, few cases have been
published.<sup><xref rid="r9" ref-type="bibr">9</xref>-<xref rid="r13" ref-type="bibr">13</xref></sup> It is classified as a subtype of type 2 reaction
and occurs more often in borderline-lepromatous patients.<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>The clinical diagnosis of type 2 reaction variant is difficult when not exist nodular
lesions characteristic of ENL, predominating lesions in edematous plaques that are
frequently misinterpreted as a type 1 reaction.</p>
      <p>Sweet's syndrome-like leprosy reaction is more easily recognized in patients with
leprosy already diagnosed than in those without previous diagnosis of the baseline
disease.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> In this case,
the use of oral corticosteroids for asthma treatment resulted in partial and
intermittent reversal of reaction feature and possibly contributed to the delay in
the diagnosis. Although the patient did not present skin lesions and neurological
changes suggestive of leprosy, chronic clinical setting and the presence of lesions
similar to those of Sweet's syndrome disseminated over the body helped in diagnostic
elucidation.</p>
      <p>In the histopathological study of type 1 reaction, a large influx of lymphocytes and
confluence of tuberculoid granuloma in the dermis are observed, which can be
dissected by edema or show central fibrinoid necrosis.<sup><xref rid="r14" ref-type="bibr">14</xref></sup> There may be also "blurring" of the dermoepidermal
junction, a missing feature in the torpid forms of borderline leprosy.</p>
      <p>Histopathology of classical type 2 leprosy reaction (ENL) is characterized by a large
influx of neutrophils in the dermis, which is permeated by groups of vacuolated
histiocytes containing bacilli. Neutrophils are distributed predominantly in the
reticular portion of the dermis, in the dermo-hypodermic junction and in the
subcutaneous tissue, and can be so numerous as to make it difficult to identify the
Virchow cells. Although the presence of vasculitis in these lesions is described, it
is a rare feature.<sup><xref rid="r15" ref-type="bibr">15</xref></sup></p>
      <p>In the case of Sweet's syndrome-like type 2 reaction, the infiltration of neutrophils
occurs predominantly in the papillary portion of the dermis concomitantly with
pronounced edema, providing enough resemblance to Sweet's syndrome lesions itself.
<sup><xref rid="r12" ref-type="bibr">12</xref></sup> In sections stained
with hematoxylin and eosin and Fite-Faraco, the pathologist should actively pursue
Virchow's cells, whose identification allows the correct diagnosis.</p>
      <p>In this case, the histopathological analysis was indicated due to the clinical
setting with disseminated skin lesions and prolonged evolution. We believe that
cases of Sweet's syndrome with atypical clinical manifestations or with no
satisfactory therapeutic response should be studied from a histopathological point
of view, since leprosy is a highly endemic disease in Brazil.</p>
      <p>In Brazil, the treatment of choice for type 2 leprosy reaction is performed with
thalidomide. Pentoxifylline is one of the alternatives in the case of
contraindications of thalidomide, as well as corticosteroids.<sup><xref rid="r16" ref-type="bibr">16</xref></sup> In our case, a woman of
childbearing age, we decided to use oral corticosteroids and pentoxifylline
initially, but the clinical presentation was refractory to these medications. Thus,
use of thalidomide after insertion of intrauterine device and application of
injectable contraceptive was proposed, according to standards of the National Health
Surveillance Agency (Anvisa).<sup><xref rid="r17" ref-type="bibr">17</xref></sup></p>
      <p>Use of systemic corticosteroids in type 2 leprosy reaction is indicated in some cases
well-established by the Ministry of Health, listed in <xref ref-type="table" rid="t1">chart 1</xref>. The authors' experience has shown that in Sweet's
syndrome-like leprosy reaction, the initial therapeutic response of corticosteroid
therapy is very good; however, to prevent the worsening of the reaction and allow
the withdrawal of corticosteroid, the introduction of thalidomide is required.
Patients with chronic forms of type 2 reaction can become dependent on
corticosteroids; then, thalidomide is the best option to avoid adverse events of
long-term therapy.<sup><xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref></sup></p>
      <table-wrap id="t1" orientation="portrait" position="float">
        <label>Chart 1</label>
        <caption>
          <p>Indications of oral corticosteroids associated with thalidomide in leprosy
reaction type 2</p>
        </caption>
        <table frame="box" rules="groups">
          <colgroup width="100%" span="1">
            <col span="1"/>
          </colgroup>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Impairment of nerves, well-stablished after palpation
and evaluation of neural function</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Presence of reaction ocular lesions, with signs of
conjunctival hyperemia with or without pain, blurred vision, with or
without cutaneous manifestations</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Inflammatory swelling of hands and feet (hands and feet
reaction)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Glomerulonephritis</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Orchiepididymitis</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Arthritis</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Severe erythema nodosum with ulceration or involvement
of internal organs</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Erythema multiforme-like, Sweet&#x2019;s syndrome-like and
Lucio&#x2019;s phenomenon (necrotizing skin reaction) reactions</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN01">
            <p>Source: Minist&#xE9;rio da Sa&#xFA;de, 2010.<sup><xref rid="r16" ref-type="bibr">16</xref></sup></p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>The reaction conditions are the main cause of damage to the nerves and disabilities
triggered by leprosy. Therefore, early diagnosis of reactions and immediate
initiation of treatment are essential, in order to prevent these
disabilities.<sup><xref rid="r5" ref-type="bibr">5</xref></sup></p>
      <p>In tropical countries, where infectious diseases such as leprosy, leishmaniasis and
sporotrichosis are endemic, it is important to consider that cases similar to
Sweet's syndrome may represent reaction presentations.<sup><xref rid="r20" ref-type="bibr">20</xref></sup> A high diagnostic suspicion and a thorough
clinical and laboratory evaluation are essential for the correct diagnosis. In the
case of Sweet's syndrome-like leprosy reaction, the identification of vacuolated
histiocytes containing bacilli in the midst of an infiltrate rich in neutrophils is
of fundamental importance.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Study performed at Hospital Federal de Bonsucesso (HFB) - Rio de Janeiro (RJ),
Brazil.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Last&#xF3;ria</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Abreu</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Leprosyreview of the epidemiological, clinical, and
etiopathogenic aspects - part 1</article-title>
          <source>An Bras Dermatol</source>
          <year>2014</year>
          <volume>89</volume>
          <fpage>205</fpage>
          <lpage>218</lpage>
          <pub-id pub-id-type="pmid">24770495</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lima-Wojcik</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Nishimori</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Santamaria</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Sweet's syndromea study of 23 cases</article-title>
          <source>An Bras Dermatol</source>
          <year>2011</year>
          <volume>86</volume>
          <fpage>265</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="pmid">21603809</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sweet</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>An acute febrile neutrophilic dermatoses</article-title>
          <source>Br J Dermatol</source>
          <year>1964</year>
          <volume>76</volume>
          <fpage>349</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="pmid">14201182</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Sweet's Syndrome - a comprehensive review of an acute febrile
neutrophilic dermatosis</article-title>
          <source>Orphanet J Rare Dis</source>
          <year>2007</year>
          <volume>2</volume>
          <fpage>34</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">17655751</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kahawita</surname>
              <given-names>IP</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Lockwood</surname>
              <given-names>DNJ</given-names>
            </name>
          </person-group>
          <article-title>Leprosy type 1 reactions and erythema nodosum
leprosum</article-title>
          <source>An Bras Dermatol</source>
          <year>2008</year>
          <volume>83</volume>
          <fpage>75</fpage>
          <lpage>82</lpage>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miranda</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Antunes</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Nery</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sales</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Sarno</surname>
              <given-names>EN</given-names>
            </name>
          </person-group>
          <article-title>Erythema multiforme in leprosy</article-title>
          <source>Mem Inst Oswaldo Cruz</source>
          <year>2012</year>
          <volume>107</volume>
          <fpage>34</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">23283451</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Contin</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Delanina</surname>
              <given-names>WFB</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>MES</given-names>
            </name>
            <name>
              <surname>Souza</surname>
              <given-names>SOTB</given-names>
            </name>
          </person-group>
          <article-title>Eritema polimorfo hans&#xEA;nico ulcerado "ab initio"uma
apresenta&#xE7;&#xE3;o at&#xED;pica de hansen&#xED;ase na faixa
virchowiana</article-title>
          <source>Hansen Int</source>
          <year>2008</year>
          <volume>33</volume>
          <fpage>35</fpage>
          <lpage>40</lpage>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kou</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
          <article-title>Severe reactional state in lepromatous leprosy simulating sweet's
syndrome</article-title>
          <source>Int J Dermatol</source>
          <year>1987</year>
          <volume>26</volume>
          <fpage>518</fpage>
          <lpage>520</lpage>
          <pub-id pub-id-type="pmid">3679660</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramos-E-Silva</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Munhoz-da-Fontoura</surname>
              <given-names>GH</given-names>
            </name>
          </person-group>
          <article-title>Leprosyuncommon presentations</article-title>
          <source>Clin Dermatol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>509</fpage>
          <lpage>514</lpage>
          <pub-id pub-id-type="pmid">16179185</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aires</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Refkalefsky Loureiro</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Villela</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sakai Valente</surname>
              <given-names>NY</given-names>
            </name>
            <name>
              <surname>Trindade</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Sweet's syndrome type leprosy reaction</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2009</year>
          <volume>23</volume>
          <fpage>467</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="pmid">18662196</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ramesh</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pahwa</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Some unusual type 2 reactions in leprosy</article-title>
          <source>Int J Dermatol</source>
          <year>2010</year>
          <volume>49</volume>
          <fpage>172</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="pmid">20465641</pub-id>
        </element-citation>
      </ref>
      <ref id="r12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heng</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Chiam</surname>
              <given-names>YT</given-names>
            </name>
            <name>
              <surname>Giam</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
          <article-title>Lepromatous leprosy in erythema nodosum leprosum reaction
mimicking Sweet's syndrome</article-title>
          <source>Int J Dermatol</source>
          <year>2011</year>
          <volume>50</volume>
          <fpage>1124</fpage>
          <lpage>1125</lpage>
          <pub-id pub-id-type="pmid">22126876</pub-id>
        </element-citation>
      </ref>
      <ref id="r13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Das</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ghosh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kundu</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Maity</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Reactional state in lepromatous leprosy simulating sweet's
syndrome</article-title>
          <source>J Assoc Physicians India</source>
          <year>2013</year>
          <volume>61</volume>
          <fpage>856</fpage>
          <lpage>858</lpage>
          <pub-id pub-id-type="pmid">24974510</pub-id>
        </element-citation>
      </ref>
      <ref id="r14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ponnaiya</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Emmanuel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Type I reaction in leprosy - a histopathological
analysis</article-title>
          <source>Indian J Lepr</source>
          <year>2013</year>
          <volume>85</volume>
          <fpage>1</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">24046908</pub-id>
        </element-citation>
      </ref>
      <ref id="r15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Muhammed</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Najeeba</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rajan</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Anza</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Binitha</surname>
              <given-names>MP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A study on histological features of lepra reactions in patients
attending the Dermatology Department of the Government Medical College,
Calicut, Kerala, India</article-title>
          <source>Lepr Rev</source>
          <year>2013</year>
          <volume>84</volume>
          <fpage>51</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">23741882</pub-id>
        </element-citation>
      </ref>
      <ref id="r16">
        <label>16</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Bvsms.saude.gov.br</collab>
            <collab>Brasil</collab>
            <collab>Minist&#xE9;rio da Sa&#xFA;de</collab>
            <collab>Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de</collab>
            <collab>Departamento de Vigil&#xE2;ncia
Epidemiol&#xF3;gica</collab>
          </person-group>
          <source>Orienta&#xE7;&#xF5;es para uso: corticosteroides em
hansen&#xED;ase</source>
          <size units="pages">52 p</size>
          <comment>(S&#xE9;rie A. Normas e Manuais T&#xE9;cnicos)</comment>
          <date-in-citation content-type="access-date">acesso 13 out
2014</date-in-citation>
          <year>2010</year>
          <publisher-loc>Bras&#xED;lia</publisher-loc>
          <publisher-name>Editora do Minist&#xE9;rio da Sa&#xFA;de</publisher-name>
          <ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/publicacoes/orientacoes_para_corticosteroides_hanseniase.pdf">
http://bvsms.saude.gov.br/bvs/publicacoes/orientacoes_para_corticosteroides_hanseniase.pdf</ext-link>
        </element-citation>
      </ref>
      <ref id="r17">
        <label>17</label>
        <element-citation publication-type="legal-doc">
          <person-group person-group-type="author">
            <collab>Saude.gov.br</collab>
            <collab>Brasil</collab>
            <collab>Minist&#xE9;rio da Sa&#xFA;de</collab>
            <collab>Ag&#xEA;ncia Nacional de Vigil&#xE2;ncia
Sanit&#xE1;ria</collab>
          </person-group>
          <article-title>Resolu&#xE7;&#xE3;o - RDC n&#xB0; 11, de 22 de mar&#xE7;o de
2011. Disp&#xF5;e sobre o controle da subst&#xE2;ncia Talidomida e do
medicamento que a contenha</article-title>
          <date-in-citation content-type="access-date">acesso 13 out
2014</date-in-citation>
          <comment>Dispon&#xED;vel em: <ext-link ext-link-type="uri" xlink:href="http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2011/res0011_21_03_2011.html">http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2011/res0011_21_03_2011.html</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="r18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Waters</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Lockwood</surname>
              <given-names>DN</given-names>
            </name>
          </person-group>
          <article-title>The role of thalidomide in the management of erythema nodosum
leprosum</article-title>
          <source>Lepr Rev</source>
          <year>2007</year>
          <volume>78</volume>
          <fpage>197</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="pmid">18035771</pub-id>
        </element-citation>
      </ref>
      <ref id="r19">
        <label>19</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Projeto diretrizes.org.br</collab>
            <collab>Sociedade Brasileira de Hansenologia</collab>
            <collab>Sociedade Brasileira de Dermatologia</collab>
            <collab>Projeto Diretrizes</collab>
          </person-group>
          <article-title>Hansen&#xED;ase: Epis&#xF3;dios Reacionais</article-title>
          <source>Associa&#xE7;&#xE3;o M&#xE9;dica Brasileira e Conselho Federal de
Medicina</source>
          <year>2003</year>
          <date-in-citation content-type="access-date">acesso 13 out
2014</date-in-citation>
          <comment>Dispon&#xED;vel em: <ext-link ext-link-type="uri" xlink:href="http://www.projetodiretrizes.org.br/projeto_diretrizes/056.pdf">http://www.projetodiretrizes.org.br/projeto_diretrizes/056.pdf</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="r20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freitas</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Valle</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Cuzzi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Brand&#xE3;o</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Zancope-Oliveira</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Galhardo</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Sweet syndrome associated with sporotrichosis</article-title>
          <source>Br J Dermatol</source>
          <year>2012</year>
          <volume>166</volume>
          <issue>1</issue>
          <fpage>212</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="pmid">21711340</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
